The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Open accessAbstract
Chemokines are small secreted proteins that orchestrate migration and positioning of immune cells within the tissues. Chemokines are essential for the function of the immune system. Accumulating evidence suggest that chemokines play important roles in tumor microenvironment. In this review we discuss an association of chemokine expression and activity within the tumor microenvironment with cancer outcome. We summarize regulation of immune cell recruitment into the tumor by chemokine-chemokine receptor interactions and describe evidence implicating chemokines in promotion of the "inflamed" immune-cell enriched tumor microenvironment. We review both tumor-promoting function of chemokines, such as regulation of tumor metastasis, and beneficial chemokine roles, including stimulation of anti-tumor immunity and response to immunotherapy. Finally, we discuss the therapeutic strategies target tumor-promoting chemokines or induce/deliver beneficial chemokines within the tumor focusing on pre-clinical studies and clinical trials going forward. The goal of this review is to provide insight into comprehensive role of chemokines and their receptors in tumor pathobiology and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“These data are complicated by reports of JAK1 mutation being associated with resistance to anti-PD1 (130).”
BackgroundThe prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Towards a knowledge-based Human Protein Atlas
Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1210-1248 · Cited by 2,440
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · cited 1×
“The rationale for this study relates to the fact that PD-L1 positive tumors are more likely to respond to anti-PD-L1 immunotherapy, even though PDL1 is not a definitive predictor of response (118, 122).”
BackgroundChemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Regulation of Interferon‐γ During Innate and Adaptive Immune Responses
(2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96002-2 · Cited by 1,655
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
The Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216 · cited 3×
“Furthermore, Benci et al. showed that prolonged IFNγ signaling contributes to tumor growth as a result of expression of interferon-driven inhibitor ligands (IDILS) which, in addition to PD-L1, include TNF Receptor Superfamily Member 14/Herpes Virus Entry Mediator (TNFRSF14), galectin9 (LGALS9), MHCII, CD28 Antigen Lig…”
BackgroundEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“For instance, treatment of ovarian cancer cells with epigenetic modifiers reversed the EZH2 and DNMT1 suppression of expression of the CXCR3 ligands, CXCL9, and CXCL10, resulting in T cell influx into the tumor and improved response to T cell transfer and anti-PD-L1 blockade therapy (160).”
BackgroundChemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“For example, in melanoma, the lack of CCR5 ligands (CCL3, CCL4, CCL5) and CXCR3 ligands (CXCL9 and CXCL10) has been associated with limited infiltration of antigen-specific T cells (103).”
BackgroundChien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046
Visualizing the generation of memory CD4 T cells in the whole body
Reinhardt, R. L., Khoruts, A., Merica, R., Zell, T., & Jenkins, M. K. (2001) · Nature · doi:10.1038/35065111 · Cited by 1,026
Stromal Cell Networks Regulate Lymphocyte Entry, Migration, and Territoriality in Lymph Nodes
Bajénoff, M., Egen, J. G., Koo, L. Y., Laugier, J. P., Brau, F., Glaichenhaus, N., & Germain, R. N. (2006) · Immunity · doi:10.1016/j.immuni.2006.10.011 · Cited by 963
Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells
Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007) · Nature Immunology · doi:10.1038/ni1513 · Cited by 931
Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.004 · Cited by 918
Self-citationINTERFEROME v2.0: an updated database of annotated interferon-regulated genes
Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., Chapman, R., & Hertzog, P. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1215 · Cited by 878
The Chemokine System in Innate Immunity
Sokol, C. L., & Luster, A. D. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016303 · Cited by 862
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Tumor entrained neutrophils inhibit seeding in the premetastatic lung
Granot, Z., Henke, E., Comen, E. A., King, T. A., Norton, L., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.012 · Cited by 782
An immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts
Ginestier, C., Liu, S., Diebel, M. E., Korkaya, H., Luo, M., Brown, M., Wicinski, J., Cabaud, O., Charafe-Jauffret, E., Birnbaum, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39397 · Cited by 747
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Kitamura, T., Qian, B.-Z., Soong, D., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 651
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
Self-citationRole of chemokines in tumor growth
Raman, D., Baugher, P. J., Thu, Y. M., & Richmond, A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.013 · Cited by 578
Self-citationCD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help
Nakanishi, Y., Lu, B., Gerard, C., & Iwasaki, A. (2009) · Nature · doi:10.1038/nature08511 · Cited by 548
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Nywening, T. M., Belt, B. A., Cullinan, D. R., Panni, R. Z., Han, B. J., Sanford, D. E., Jacobs, R. C., Ye, J., Patel, A. A., Gillanders, W. E., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-313738 · Cited by 489
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W., Wang, J., Wang, X., & Fu, Y.-X. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 472
Obermajer, N., Muthuswamy, R., Odunsi, K., Edwards, R. P., & Kalinski, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2449 · Cited by 464
Zou, L., Barnett, B., Safah, H., LaRussa, V. F., Evdemon-Hogan, M., Mottram, P., Wei, S., David, O., Curiel, T. J., & Zou, W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1987 · Cited by 456
D’Ambrosio, D., Iellem, A., Bonecchi, R., Mazzeo, D., Sozzani, S., Mantovani, A., & Sinigaglia, F. (1998) · PubMed · Cited by 438
Pham, T. H. M., Okada, T., Matloubian, M., Lo, C. G., & Cyster, J. G. (2008) · Immunity · doi:10.1016/j.immuni.2007.11.017 · Cited by 427
Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports · doi:10.1038/srep00765 · Cited by 426
Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition
Nakayamada, S., Kanno, Y., Takahashi, H., Jankovic, D., Lu, K. T., Johnson, T. A., Sun, H.-W., Vahedi, G., Hakim, O., Handon, R., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.012 · Cited by 411
Innate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Immune regulation by atypical chemokine receptors
Nibbs, R. J. B., & Graham, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3544 · Cited by 407
Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., Luu, T., Li, A. X., Wu, X., Ye, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3567 · Cited by 407
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
D’Ambrosio, D., Iellem, A., Bonecchi, R., Mazzeo, D., Sozzani, S., Mantovani, A., & Sinigaglia, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5111 · Cited by 372
Azenshtein, E., Luboshits, G., Shina, S., Neumark, E., Shahbazian, D., Weil, M., Wigler, N., Keydar, I., & Ben‐Baruch, A. (2002) · PubMed · Cited by 371
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368
Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice
Sawanobori, Y., Ueha, S., Kurachi, M., Shimaoka, T., Talmadge, J. E., Abe, J., Shono, Y., Kitabatake, M., Kakimi, K., Mukaida, N., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136895 · Cited by 367
CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer
Wang, D., Sun, H., Wei, J., Cen, B., & DuBois, R. N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3199 · Cited by 356
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature
Murphy, P. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.227 · Cited by 342
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Heterogeneity of Human CD4 + T Cells Against Microbes
Sallusto, F. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112056 · Cited by 336
EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells
Li, J., Lu, E., Yi, T., & Cyster, J. G. (2016) · Nature · doi:10.1038/nature17947 · Cited by 315
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells
Islam, S. A., Chang, D. S., Colvin, R. A., Byrne, M. H., McCully, M. L., Moser, B., Lira, S. A., Charo, I. F., & Luster, A. D. (2011) · Nature Immunology · doi:10.1038/ni.1984 · Cited by 307
Taki, M., Abiko, K., Baba, T., Hamanishi, J., Yamaguchi, K., Murakami, R., Yamanoi, K., Horikawa, N., Hosoe, Y., Nakamura, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03966-7 · Cited by 296
Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment
Scala, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0914 · Cited by 290
Saji, H., Koike, M., Yamori, T., Saji, S., Seiki, M., Matsushima, K., & Toi, M. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1085::aid-cncr1424>3.0.co;2-k · Cited by 288
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 278
Gut microbiota modulate T cell trafficking into human colorectal cancer
Cremonesi, E., Governa, V., Garzon, J. F. G., Mele, V., Amicarella, F., Muraro, M. G., Trella, E., Galati-Fournier, V., Oertli, D., Däster, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313498 · Cited by 275
Chemokine and chemotactic signals in dendritic cell migration
Tiberio, L., Del Prete, A., Schioppa, T., Sozio, F., Bosisio, D., & Sozzani, S. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0005-3 · Cited by 256
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 246
Hong, M., Puaux, A.-L., Huang, C., Loumagne, L., Tow, C., Mackay, C., Kato, M., Prévost-Blondel, A., Avril, M.-F., Nardin, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1466 · Cited by 246
Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
Righi, E., Kashiwagi, S., Yuan, J., Santosuosso, M., Leblanc, P., Ingraham, R., Forbes, B., Edelblute, B., Collette, B., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3143 · Cited by 245
Cutting Edge: Distinct Waves of BCL6 Expression during T Follicular Helper Cell Development
Baumjohann, D., Okada, T., & Ansel, K. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101393 · Cited by 229
Role for CCR7 Ligands in the Emigration of Newly Generated T Lymphocytes from the Neonatal Thymus
Ueno, T., Hara, K., Willis, M. S., Malin, M. A., Höpken, U. E., Gray, D. H. D., Matsushima, K., Lipp, M., Springer, T. A., Boyd, R. L., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00267-4 · Cited by 222
Sebzda, E., Zou, Z., Lee, J. S., Wang, T., & Kahn, M. L. (2008) · Nature Immunology · doi:10.1038/ni1565 · Cited by 213
Ramírez-Valle, F., Gray, E. E., & Cyster, J. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508990112 · Cited by 209
Chemokines and Chemokine Receptors in Lymphoid Tissue Dynamics
Schulz, O., Hammerschmidt, S. I., Moschovakis, G. L., & Förster, R. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055649 · Cited by 192
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers
Elion, D. L., Jacobson, M. E., Hicks, D. J., Rahman, B., Sanchez, V., Gonzales-Ericsson, P. I., Fedorova, O., Pyle, A. M., Wilson, J. T., & Cook, R. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0730 · Cited by 179
Ato, M., Stäger, S., Engwerda, C. R., & Kaye, P. M. (2002) · Nature Immunology · doi:10.1038/ni861 · Cited by 174
Moon, E. K., Wang, L.-C. S., Bekdache, K., Lynn, R. C., Lo, A., Thorne, S. H., & Albelda, S. M. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1395997 · Cited by 174
Kumar, S., Wilkes, D. W., Samuel, N., Blanco, M. A., Nayak, A., Alicea-Torres, K., Gluck, C., Sinha, S., Gabrilovich, D., & Chakrabarti, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99673 · Cited by 173
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
Zhao, E., Wang, L., Dai, J., Kryczek, I., Wei, S., Vatan, L., Altuwaijri, S., Sparwasser, T. D., Wang, G., Keller, E. T., et al. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18480 · Cited by 170
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 170
Bao, X., Moseman, E. A., Saito, H., Petryanik, B., Thiriot, A., Hatakeyama, S., Ito, Y., Kawashima, H., Yamaguchi, Y., Lowe, J. B., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.018 · Cited by 167
Zboralski, D., Hoehlig, K., Eulberg, D., Frömming, A., & Vater, A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0303 · Cited by 166
Wu, H., Hwang‐Verslues, W. W., Lee, W.-H., Huang, C.-K., Wei, P., Chen, C.-L., Shew, J., Lee, E. Y.-H. P., Jeng, Y., Tien, Y., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141702 · Cited by 165
Singh, S., Sadanandam, A., Nannuru, K. C., Varney, M. L., Mayer‐Ezell, R., Bond, R. W., & Singh, R. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2387 · Cited by 160
Li, C. X., Ling, C. C., Shao, Y., Xu, A., Li, X. C., Ng, K. T.-P., Liu, X. B., Ma, Y. Y., Qi, X., Liu, H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.032 · Cited by 160
Enhancement of T cell recruitment and infiltration into tumours
Oelkrug, C., & Ramage, J. M. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12382 · Cited by 153
Lunardi, S., Jamieson, N. B., Lim, S. Y., Griffiths, K., Carvalho‐Gaspar, M., Al‐Assar, O., Yameen, S., Carter, R. C., McKay, C. J., Spoletini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2519 · Cited by 149
Pernas, S., Martín, M., Kaufman, P. A., Gil-Martín, M., Pardo, P. G., López‐Tarruella, S., Manso, L., Ciruelos, E. M., Fidalgo, J. A. P., Hernándo, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30147-5 · Cited by 148
Essential role of CCL21 in establishment of central self-tolerance in T cells
Kozai, M., Kubo, Y., Katakai, T., Kondo, H., Kiyonari, H., Schaeuble, K., Luther, S. A., Ishimaru, N., Ohigashi, I., & Takahama, Y. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161864 · Cited by 138
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion
Jiao, X., Velasco-Velázquez, M. A., Wang, M., Li, Z., Rui, H., Peck, A. R., Korkola, J. E., Chen, X., Xu, S., DuHadaway, J. B., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0915 · Cited by 138
Varney, M. L., Johansson, S. L., & Singh, R. K. (2005) · American Journal of Clinical Pathology · doi:10.1309/vpl5r3jr7f1d6v03 · Cited by 133
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W. P., Wang, J., Wang, X., & Fu, Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.011 · Cited by 128
CC Chemokine Receptor 7–dependent and –independent Pathways for Lymphocyte Homing
Henning, G., Ohl, L., Junt, T., Reiterer, P., Brinkmann, V., Nakano, H., Hohenberger, W., Lipp, M., & Förster, R. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.12.1875 · Cited by 125
Dermal IL‐17‐producing γδ T cells establish long‐lived memory in the skin
Hartwig, T., Pantelyushin, S., Croxford, A. L., Kulig, P., & Becher, B. (2015) · European Journal of Immunology · doi:10.1002/eji.201545883 · Cited by 120
Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115
Self-citationLi, B., Wang, Z., Wu, H., Xue, M., Lin, P., Wang, S., Lin, N., Huang, X., Pan, W., Liu, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3801 · Cited by 114
Moesta, A. K., Cooke, K. S., Piasecki, J., Mitchell, P., Rottman, J. B., Fitzgerald, K. L., Zhan, J., Yang, B., Le, T., Belmontes, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0681 · Cited by 110
CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion
Zhu, H., Gu, Y., Xue, Y., Yuan, M., Cao, X., & Liu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.23020 · Cited by 106
Varney, M. L., Li, A., Davé, B. J., Bucana, C. D., Johansson, S. L., & Singh, R. K. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006814.48627.bd · Cited by 101
Yang, J., Kumar, A., Vilgelm, A. E., Chen, S., Ayers, G. D., Novitskiy, S. V., Joyce, S., & Richmond, A. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0045 · Cited by 99
Self-citationCCR5 Revisited: How Mechanisms of HIV Entry Govern AIDS Pathogenesis
Brelot, A., & Chakrabarti, L. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.027 · Cited by 96
Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment
Vilgelm, A. E., Johnson, C. A., Prasad, N., Yang, J., Chen, S.-C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv406 · Cited by 95
CXCR3+ Regulatory T Cells Control TH1 Responses in Crescentic GN
Paust, H., Riedel, J.-H., Krebs, C. F., Turner, J., Brix, S. R., Krohn, S., Velden, J., Wiech, T., Kaffke, A., Peters, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015020203 · Cited by 94
Woodruff, M. C., Heesters, B. A., Herndon, C. N., Groom, J. R., Thomas, P. G., Luster, A. D., Turley, S. J., & Carroll, M. C. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132327 · Cited by 91
Zhang, Y., Roth, T. L., Gray, E. E., Chen, H., Rodda, L. B., Yin, L., Ventura, P. B., Villeda, S., Crocker, P. R., & Cyster, J. G. (2016) · eLife · doi:10.7554/elife.18156 · Cited by 89
Erhardt, A., Wegscheid, C., Claass, B., Carambia, A., Herkel, J., Mittrücker, H., Panzer, U., & Tiegs, G. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003750 · Cited by 76
Kim, C. H., Nagata, K., & Butcher, E. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.1.152 · Cited by 75
Hu, Z., Chen, J., Zhou, S., Yang, N., Duan, S., Zhang, Z., Su, J., He, J., Zhang, Z., Lü, X., et al. (2017) · Theranostics · doi:10.7150/thno.16236 · Cited by 75
Dürr, C., Pfeifer, D., Claus, R., Schmitt-Graeff, A. H., Gerlach, U. V., Graeser, R., Krüger, S., Gerbitz, A., Negrin, R. S., Finke, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1943 · Cited by 63
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma
Sharma, B., Singh, S., Varney, M. L., & Singh, R. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728221003652471 · Cited by 61
Wang, N., Docherty, F., Brown, H. K., Reeves, K. J., Fowles, A. C. M., Lawson, M. A., Ottewell, P. D., Holen, I., Croucher, P. I., & Eaton, C. L. (2015) · The FASEB Journal · doi:10.1096/fj.14-266379 · Cited by 57
Decalf, J., Tarbell, K. V., Casrouge, A., Price, J. D., Linder, G., Mottez, E., Sultanik, P., Mallet, V. O., Pol, S., Duffy, D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506145 · Cited by 56
Tumour radiosensitivity is associated with immune activation in solid tumours
Ström, T., Harrison, L. B., Giuliano, A. R., Schell, M. J., Eschrich, S. A., Berglund, A., Fulp, W. J., Thapa, R., Coppola, D., Kim, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.001 · Cited by 55
Jamal, R., Lapointe, R., Cocolakis, E., Thébault, P., Kazemi, S., Friedmann, J. E., Dionne, J., Cailhier, J., Bélanger, K., Ayoub, J.-P., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0290-x · Cited by 55
Shen, Z., Wang, J., Huang, Q., Shi, Y. X., Wei, Z., Zhang, X., Qiu, Y., Zhang, M., Wang, Y., Qin, W., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0310-x · Cited by 54
Sorrentino, C., Ciummo, S. L., Cipollone, G., Caputo, S., Bellone, M., & Carlo, E. D. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3117 · Cited by 52
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Purohit, A., Varney, M. L., Rachagani, S., Ouellette, M. M., Batra, S. K., & Singh, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6906 · Cited by 46
Chen, X., Ma, W., Zhang, T., Wu, L., & Qi, H. (2015) · Protein & Cell · doi:10.1007/s13238-015-0210-0 · Cited by 45
How Do Chemokine/Chemokine Receptor Activations Affect Tumorigenesis?
Richmond, A. J., Fan, G.-H., Dhawan, P., & Yang, J. (2004) · Novartis Foundation symposium · doi:10.1002/0470856734.ch6 · Cited by 44
Self-citationLavender, N., Yang, J., Chen, S., Sai, J., Johnson, C. A., Owens, P., Ayers, G. D., & Richmond, A. J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3074-2 · Cited by 44
Self-citationZhang, H., Li, Z., Wang, L., Tian, G., Tian, J., Yang, Z., Cao, G., Zhou, H. Y., Zhao, L., Wu, Z., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00129 · Cited by 42
Chemokine-Driven CD4 + T Cell Homing: New Concepts and Recent Advances
Whyte, C. E., Foeng, J., Comerford, I., & McColl, S. R. (2017) · Advances in immunology · doi:10.1016/bs.ai.2017.03.001 · Cited by 42
CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis
Gao, D. F., Cazares, L. H., & Fish, E. N. (2017) · BMC Cancer · doi:10.1186/s12885-017-3817-0 · Cited by 42
Stoll, G., Pol, J. G., Soumelis, V., Zitvogel, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484980 · Cited by 42
Ba, H., Li, B., Li, X., Li, C., Feng, A., Zhu, Y., Wang, J., Li, Z., & Yin, B. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2016.12.028 · Cited by 41
Kemp, D. M., Pidich, A., Larijani, M., Jonas, R. A., Lash, E., Sato, T., Terai, M., Pizzol, M. D., Allegretti, M., Igoucheva, O., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14803 · Cited by 40
Damås, J. K., Landrø, L., Fevang, B., Heggelund, L., Tjønnfjord, G. E., Fløisand, Y., Halvorsen, B. L., Frøland, S. S., & Aukrust, P. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03976.x · Cited by 39
Theodoraki, M., Yerneni, S. S., Sarkar, S. N., Orr, B. C., Muthuswamy, R., Voyten, J., Modugno, F., Jiang, W., Grimm, M. J., Basse, P. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3985 · Cited by 38
CXCR4-Positive Subset of Glioma Is Enriched for Cancer Stem Cells
Zheng, X., Xie, Q., Li, S., & Zhang, W. (2011) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504012x13340632812631 · Cited by 37
Gajewski, T. F., Zha, Y., Thurner, B., & Schuler, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9002 · Cited by 31
Recent developments in small molecule therapies for renal cell carcinoma
Song, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.007 · Cited by 31
Uehara, J., Ohkuri, T., Kosaka, A., Ishibashi, K., Hirata, Y., Ohara, K., Nagato, T., Oikawa, K., Aoki, N., Harabuchi, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.072 · Cited by 29
Yagawa, Y., Robertson‐Tessi, M., Zhou, S. L., Anderson, A. R. A., Mulé, J. J., & Mailloux, A. W. (2017) · Scientific Reports · doi:10.1038/s41598-017-15924-2 · Cited by 25
T-cell trafficking into sites of inflammation
Hamann, A. (2000) · British journal of rheumatology · doi:10.1093/rheumatology/39.7.696 · Cited by 22
Ignacio, R. M. C., Dong, Y.-L., Kabir, S. M., Choi, H., Lee, E.-S., Wilson, A. J., Beeghly-Fadiel, A. C., Whalen, M. M., & Son, D. (2018) · Oncotarget · doi:10.18632/oncotarget.24231 · Cited by 22
Xue, M.-Q., Li, J., Sang, J., Su, L., & Yao, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16893 · Cited by 20
Ijichi, H. (2012) · OncoImmunology · doi:10.4161/onci.19402 · Cited by 19
The prognostic value of CXC chemokine receptor 2 (CXCR2) in cancers: a meta-analysis
Qiao, B., Luo, W., Liu, Y., Wang, J., Liu, C., Liu, Z., Chen, S., Gu, J., Qi, X., & Wu, T. (2017) · Oncotarget · doi:10.18632/oncotarget.23492 · Cited by 19
van der Voort, R., Volman, T. J. H., Verweij, V., Linssen, P. C. M., Maas, F., Hebeda, K. M., & Dolstra, H. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.12.014 · Cited by 12
Vilgelm, A. E., & Richmond, A. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009299 · Cited by 12
Self-citationCXCR2 Inhibition in Pancreatic Cancer: Opportunities for Immunotherapy?
Morton, J. P., & Sansom, O. J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0115 · Cited by 12
CXCR2-targeted therapy for pancreatic cancer
Dart, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.67 · Cited by 7
Cited by
Barkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01141-9 · Cited by 532
Gruber, C. N., Patel, R. S., Trachtman, R., Lepow, L., Amanat, F., Krammer, F., Wilson, K. M., Onel, K., Geanon, D., Tuballes, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.034 · Cited by 551
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 348
Self-citationDifferentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Basu, A., Ramamoorthi, G., Albert, G., Gallen, C., Beyer, A., Snyder, C., Koski, G., Disis, M. L., Czerniecki, B. J., & Kodumudi, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669474 · Cited by 321
Metadata
- Authors
- Vilgelm, A. E., & Richmond, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-02-27
- Volume
- 10
- Pages
- 333-333
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2911977097
- Cited by
- 379
- References
- 169
- FWCI
- 15.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.